市場調査レポート
商品コード
1064437

BCL-2 (B細胞リンパ腫-2) 阻害剤の世界市場:2022~2026年

Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2022-2026

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 120 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
BCL-2 (B細胞リンパ腫-2) 阻害剤の世界市場:2022~2026年
出版日: 2022年03月03日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 120 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のBCL-2 (B細胞リンパ腫-2) 阻害剤の市場規模は、2022年から2026年の間に14億3,000万米ドルの成長が見込まれ、予測期間中のCAGRは12.60%となる見込みです。

この市場は、高齢者人口の増加や血液悪性腫瘍に対する意識の高まりによって牽引されています。

当レポートでは、世界のBCL-2 (B細胞リンパ腫-2) 阻害剤市場について調査分析し、市場規模、ファイブフォース分析、製品別市場セグメンテーション、顧客情勢、地域情勢、ベンダー情勢、ベンダー分析を提供しています。

目次

第1章 エグゼクティブサマリー

  • 市場概要

第2章 市場情勢

  • 市場のエコシステム
  • バリューチェーン分析

第3章 市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模:2021年
  • 市場の見通し:予測(2021~2026年)

第4章 ファイブフォース分析

  • ファイブフォースの要約
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • ライバルの脅威
  • 市況

第5章 市場セグメンテーション:製品別

  • 市場セグメント
  • 比較:製品別
  • 併用療法:市場規模と予測(2021~2026年)
  • 単剤療法:市場規模と予測(2021~2026年)
  • 市場機会:製品別

第6章 顧客情勢

  • 概要

第7章 地域情勢

  • 地域セグメンテーション
  • 地域比較
  • 北米:市場規模と予測(2021~2026年)
  • 欧州:市場規模と予測(2021~2026年)
  • アジア:市場規模と予測(2021~2026年)
  • その他の地域:市場規模と予測(2021~2026年)
  • 主要国
  • 市場機会:地域情勢別

第8章 促進要因、課題、および動向

  • 市場の促進要因
  • 市場の課題
  • 市場動向

第9章 ベンダー情勢

  • 概要
  • 革新の情勢
  • 競合シナリオ

第10章 ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • AbbVie Inc.
  • Ascentage Pharma Group International
  • AstraZeneca Plc
  • BioGene Ltd.
  • F. Hoffmann La Roche Ltd
  • Servier

第11章 付録

  • 調査範囲
  • 通貨換算レート(米ドル)
  • 調査手法
  • 略語のリスト
目次
Product Code: IRTNTR72723

Technavio has been monitoring the BCL-2 (B-cell Lymphoma 2) inhibitors market and it is poised to grow by $ 1.43 bn during 2022-2026, progressing at a CAGR of 12.60% during the forecast period. Our report on the BCL-2 (B-cell Lymphoma 2) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by rise in geriatric population and growing awareness about hematological malignancies. In addition, rise in geriatric population is anticipated to boost the growth of the market as well.

The BCL-2 (B-cell Lymphoma 2) inhibitors market analysis includes the product segment and geographic landscape.

Technavio's BCL-2 (B-cell Lymphoma 2) inhibitors market is segmented as below:

By Product

  • Combination therapy
  • Monotherapy

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the high target affinity and specificity of BCL-2 inhibitorsas one of the prime reasons driving the BCL-2 (B-cell Lymphoma 2) inhibitors market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on BCL-2 (B-cell Lymphoma 2) inhibitors market covers the following areas:

  • BCL-2 (B-cell Lymphoma 2) inhibitors market sizing
  • BCL-2 (B-cell Lymphoma 2) inhibitors market forecast
  • BCL-2 (B-cell Lymphoma 2) inhibitors market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading BCL-2 (B-cell Lymphoma 2) inhibitors market vendors that include AbbVie Inc., Ascentage Pharma Group International, AstraZeneca Plc, BioGene Ltd., F. Hoffmann La Roche Ltd., and Servier. Also, the BCL-2 (B-cell Lymphoma 2) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1. Executive Summary

  • 1.1 Market Overview
  • Exhibit 01: Key Finding 1
  • Exhibit 02: Key Finding 2
  • Exhibit 03: Key Finding 3
  • Exhibit 04: Key Finding 5
  • Exhibit 05: Key Finding 6
  • Exhibit 06: Key Finding 7
  • Exhibit 07: Key Finding 8

2. Market Landscape

  • 2.1 Market ecosystem
    • 2.1.1 Parent Market
    • Exhibit 08 Parent market
  • Exhibit 09: Market characteristics
  • 2.2 Value Chain Analysis
  • Exhibit 10: Value Chain Analysis: Pharmaceuticals
    • 2.2.1 Research and development (R&D) and drug discovery:
    • 2.2.2 Integration and product development:
    • 2.2.3 Manufacturing:
    • 2.2.4 Outbound logistics:
    • 2.2.5 Marketing and sales:
    • 2.2.6 Support services:
    • 2.2.7 Innovation

3. Market Sizing

  • 3.1 Market definition
  • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021 - 2026
  • Exhibit 13: Global - Market size and forecast 2021 - 2026 ($ million)
  • Exhibit 14: Global market: Year-over-year growth 2021 - 2026 (%)

4. Five Forces Analysis

  • 4.1 Five Forces Summary
  • Exhibit 15: Five forces analysis 2021 - 2026
  • 4.2 Bargaining power of buyers
  • Exhibit 16: Bargaining power of the buyer
  • 4.3 Bargaining power of suppliers
  • Exhibit 17: Bargaining power of the supplier
  • 4.4 Threat of new entrants
  • Exhibit 18: Threat of new entrants
  • 4.5 Threat of substitutes
  • Exhibit 19: Threat of substitutes
  • 4.6 Threat of rivalry
  • Exhibit 20: Threat of rivalry
  • 4.7 Market condition
  • Exhibit 21: Market condition - Five forces 2021

5. Market Segmentation by Product

  • 5.1 Market segments
  • Exhibit 22: Product Market share 2021 - 2026 (%)
  • 5.2 Comparison by Product
  • Exhibit 23: Comparison by Product
  • 5.3 Combination therapy - Market size and forecast 2021-2026
  • Exhibit 24: Combination therapy - Market size and forecast 2021-2026 ($ million)
  • Exhibit 25: Combination therapy - Year-over-year growth 2021-2026 (%)
  • 5.4 Monotherapy - Market size and forecast 2021-2026
  • Exhibit 26: Monotherapy - Market size and forecast 2021-2026 ($ million)
  • Exhibit 27: Monotherapy - Year-over-year growth 2021-2026 (%)
  • 5.5 Market opportunity by Product
  • Exhibit 28: Market opportunity by Product

6. Customer landscape

    • Technavio-s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
  • 6.1 Overview
  • Exhibit 29: Customer landscape

7. Geographic Landscape

  • 7.1 Geographic segmentation
  • Exhibit 30: Market share By Geographical Landscape 2021-2026 (%)
  • 7.2 Geographic comparison
  • Exhibit 31: Geographic comparison
  • 7.3 North America - Market size and forecast 2021-2026
  • Exhibit 32: North America - Market size and forecast 2021-2026($ million)
  • Exhibit 33: North America - Year-over-year growth 2021-2026 (%)
  • 7.4 Europe- Market size and forecast 2021-2026
  • Exhibit 34: Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibit 35: Europe- Year-over-year growth 2021-2026 (%)
  • 7.5 Asia- Market size and forecast 2021-2026
  • Exhibit 36: Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibit 37: Asia - Year-over-year growth 2021-2026(%)
  • 7.6 ROW - Market size and forecast 2021-2026
  • Exhibit 38: ROW - Market size and forecast 2021-2026 ($ million)
  • Exhibit 39: ROW - Year-over-year growth 2021-2026 (%)
  • 7.7 Key leading countries
  • Exhibit 40: Key leading countries
  • 7.8 Market opportunity By Geographical Landscape
  • Exhibit 41: Market opportunity By Geographical Landscape ($ million)

8. Drivers, Challenges, and Trends

  • 8.1 Market drivers
    • 8.1.1 Rise in geriatric population
    • 8.1.2 Growing awareness about hematological malignancies
    • 8.1.3 High target affinity and specificity of BCL-2 inhibitors
  • 8.2 Market challenges
    • 8.2.1 Availability of substitutes
  • Exhibit 42: Some of the substitute drugs for BCL-2 inhibitor lead molecule:
    • 8.2.2 Adverse effects of BCL-2 inhibitors
    • 8.2.3 Drug resistance
  • Exhibit 43: Impact of drivers and challenges
  • 8.3 Market trends
    • 8.3.1 Increase of patient assistance programs
    • 8.3.2 Growing approval of combination therapy
    • 8.3.3 Development of novel formulations

9. Vendor Landscape

  • 9.1 Overview
  • Exhibit 44: Vendor landscape
  • 9.2 Landscape disruption
  • Exhibit 45: Landscape disruption
  • Exhibit 46: Industry Risk
  • 9.3 Competitive Scenario

10. Vendor Analysis

  • 10.1 Vendors covered
  • Exhibit 47: Vendors covered
  • 10.2 Market positioning of vendors
  • Exhibit 48: Market positioning of vendors
  • 10.3 AbbVie Inc.
  • Exhibit 49: AbbVie Inc. - Overview
  • Exhibit 50: AbbVie Inc. - Product and service
  • Exhibit 51: AbbVie Inc. - Key offerings
  • 10.4 Ascentage Pharma Group International
  • Exhibit 52: Ascentage Pharma Group International - Overview
  • Exhibit 53: Ascentage Pharma Group International - Business segments
  • Exhibit 54: Ascentage Pharma Group International - Key offerings
  • Exhibit 55: Ascentage Pharma Group International - Segment focus
  • 10.5 AstraZeneca Plc
  • Exhibit 56: AstraZeneca Plc - Overview
  • Exhibit 57: AstraZeneca Plc - Product and service
  • Exhibit 58: AstraZeneca Plc - Key offerings
  • 10.6 BioGene Ltd.
  • Exhibit 59: BioGene Ltd. - Overview
  • Exhibit 60: BioGene Ltd. - Product and service
  • Exhibit 61: BioGene Ltd. - Key offerings
  • 10.7 F. Hoffmann La Roche Ltd
  • Exhibit 62: F. Hoffmann La Roche Ltd. - Overview
  • Exhibit 63: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibit 64: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibit 65: F. Hoffmann La Roche Ltd. - Segment focus
  • 10.8 Servier
  • Exhibit 66: Servier - Overview
  • Exhibit 67: Servier - Business segments
  • Exhibit 68: Servier - Key offerings
  • Exhibit 69: Servier - Segment focus

11. Appendix

  • 11.1 Scope of the report
    • 11.1.1 Market definition
    • 11.1.2 Objectives
    • 11.1.3 Notes and caveats
  • 11.2 Currency conversion rates for US$
  • Exhibit 70: Currency conversion rates for US$
  • 11.3 Research Methodology
  • Exhibit 71: Research Methodology
  • Exhibit 72: Validation techniques employed for market sizing
  • Exhibit 73: Information sources
  • 11.4 List of abbreviations
  • Exhibit 74: List of abbreviations

Exhibits

  • Exhibits1: Key Finding 1
  • Exhibits2: Key Finding 2
  • Exhibits3: Key Finding 3
  • Exhibits4: Key Finding 5
  • Exhibits5: Key Finding 6
  • Exhibits6: Key Finding 7
  • Exhibits7: Key Finding 8
  • Exhibits8: Parent market
  • Exhibits9: Market characteristics
  • Exhibits10: Offerings of vendors included in the market definition
  • Exhibits11: Market segments
  • Exhibits12: Global - Market size and forecast 2021 - 2026 ($ million)
  • Exhibits13: Global market: Year-over-year growth 2021 - 2026 (%)
  • Exhibits14: Five forces analysis 2021 & 2026
  • Exhibits15: Bargaining power of buyers
  • Exhibits16: Bargaining power of suppliers
  • Exhibits17: Threat of new entrants
  • Exhibits18: Threat of substitutes
  • Exhibits19: Threat of rivalry
  • Exhibits20: Market condition - Five forces 2021
  • Exhibits21: Product - Market share 2021-2026 (%)
  • Exhibits22: Comparison by Product
  • Exhibits23: Combination therapy - Market size and forecast 2021-2026 ($ million)
  • Exhibits24: Combination therapy - Year-over-year growth 2021-2026 (%)
  • Exhibits25: Monotherapy - Market size and forecast 2021-2026 ($ million)
  • Exhibits26: Monotherapy - Year-over-year growth 2021-2026 (%)
  • Exhibits27: Market opportunity by Product
  • Exhibits28: Customer landscape
  • Exhibits29: Market share By Geographical Landscape 2021-2026 (%)
  • Exhibits30: Geographic comparison
  • Exhibits31: North America - Market size and forecast 2021-2026 ($ million)
  • Exhibits32: North America - Year-over-year growth 2021-2026 (%)
  • Exhibits33: Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibits34: Europe - Year-over-year growth 2021-2026 (%)
  • Exhibits35: Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibits36: Asia - Year-over-year growth 2021-2026 (%)
  • Exhibits37: ROW - Market size and forecast 2021-2026 ($ million)
  • Exhibits38: ROW - Year-over-year growth 2021-2026 (%)
  • Exhibits39: Key leading countries
  • Exhibits40: Market opportunity By Geographical Landscape ($ million)
  • Exhibits41: Impact of drivers and challenges
  • Exhibits42: Vendor landscape
  • Exhibits43: Landscape disruption
  • Exhibits44: Industry risks
  • Exhibits45: Vendors covered
  • Exhibits46: Market positioning of vendors
  • Exhibits47: AbbVie Inc. - Overview
  • Exhibits48: AbbVie Inc. - Product and service
  • Exhibits49: AbbVie Inc. - Key offerings
  • Exhibits50: AbbVie Inc. - Key customers
  • Exhibits51: AbbVie Inc. - Segment focus
  • Exhibits52: Ascentage Pharma Group International - Overview
  • Exhibits53: Ascentage Pharma Group International - Business segments
  • Exhibits54: Ascentage Pharma Group International - Key offerings
  • Exhibits55: Ascentage Pharma Group International - Key customers
  • Exhibits56: Ascentage Pharma Group International - Segment focus
  • Exhibits57: AstraZeneca Plc - Overview
  • Exhibits58: AstraZeneca Plc - Product and service
  • Exhibits59: AstraZeneca Plc - Key offerings
  • Exhibits60: AstraZeneca Plc - Key customers
  • Exhibits61: AstraZeneca Plc - Segment focus
  • Exhibits62: BioGene Ltd. - Overview
  • Exhibits63: BioGene Ltd. - Product and service
  • Exhibits64: BioGene Ltd. - Key offerings
  • Exhibits65: BioGene Ltd. - Key customers
  • Exhibits66: BioGene Ltd. - Segment focus
  • Exhibits67: F. Hoffmann La Roche Ltd. - Overview
  • Exhibits68: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibits69: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibits70: F. Hoffmann La Roche Ltd. - Key customers
  • Exhibits71: F. Hoffmann La Roche Ltd. - Segment focus
  • Exhibits72: Servier - Overview
  • Exhibits73: Servier - Business segments
  • Exhibits74: Servier - Key offerings
  • Exhibits75: Servier - Key customers
  • Exhibits76: Servier - Segment focus
  • Exhibits77: Currency conversion rates for US$
  • Exhibits78: Research Methodology
  • Exhibits79: Validation techniques employed for market sizing
  • Exhibits80: Information sources
  • Exhibits81: List of abbreviations